Pancreatic Cancer Research

ResearcherWashington University in St. LouisActive in the last 2 years

Dung Thi Le

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2110-7697; OpenAlex author ID A5011776853, A5128403110; NIH RePORTER profile ID 8465002. Sources: funder_awards.

Their work

Papers
53 (first author 1, last author 5)
Trials
10 (principal investigator on 9)
Grants
4
Labs led
1
Collaborators
166
Papers, trials and grants by year

2009: 1 trial · 2010: none · 2011: 2 papers, 2 trials · 2012: 3 papers · 2013: 5 papers · 2014: 2 papers, 1 trial, 1 grant · 2015: 4 papers, 2 trials, 1 grant · 2016: 2 papers · 2017: 3 papers, 1 trial, 1 grant · 2018: 5 papers, 1 trial · 2019: 2 papers · 2020: 4 papers, 1 trial · 2021: 3 papers, 1 trial · 2022: 5 papers · 2023: 3 papers · 2024: 3 papers · 2025: 2 papers, 1 grant · 2026: 5 papers

Papers 50 of 53

  1. Postsurgical circulating tumor DNA as a prognostic biomarker for relapse of resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.gassur.2026.102359↗
  2. The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II… Co-author DOI 10.1038/s41467-026-69294-3↗
  3. A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC. Co-author DOI 10.1158/2326-6066.cir-25-0545↗
  4. Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses. Co-author DOI 10.1158/2326-6066.cir-25-1126↗
  5. Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma. Co-author DOI 10.3389/fimmu.2026.1715761↗
  6. Phase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and … Co-author DOI 10.1016/j.ijrobp.2024.10.039↗
  7. A phase 2 trial of CXCR4 antagonism and PD1 inhibition in metastatic pancreatic adenocarcinoma reveals recruitment of T cells but also immunosuppressive macrop… Co-author DOI 10.1080/2162402x.2025.2543614↗
  8. Clinical outcomes of liposomal irinotecan in patients with advanced pancreatic cancer previously treated with conventional irinotecan: A meta-analysis of real-… Co-author DOI 10.1002/cncr.35479↗
  9. Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032). Last author DOI 10.1136/jitc-2023-007883↗
  10. Phosphodiesterase-5 inhibition collaborates with vaccine-based immunotherapy to reprogram myeloid cells in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci.insight.179292↗
  11. A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with r… Co-author DOI 10.1038/s41467-023-39196-9↗
  12. Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer. Co-author DOI 10.1158/2767-9764.crc-23-0230↗
  13. Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a … Co-author DOI 10.3389/fonc.2023.1250136↗
  14. High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients trea… Co-author DOI 10.1002/cam4.4527↗
  15. Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled… Co-author DOI 10.1016/j.prro.2022.02.009↗
  16. Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/2767-9764.crc-22-0343↗
  17. RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1200/po.21.00404↗
  18. Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderlin… Co-author DOI 10.1245/s10434-021-11202-8↗
  19. Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. Co-author DOI 10.1016/j.canlet.2020.10.039↗
  20. Survival Outcomes of Adjuvant Chemotherapy Combined With Radiation Versus Chemotherapy Alone After Pancreatectomy for Distal Pancreatic Adenocarcinoma: A Singl… Co-author DOI 10.1097/mpa.0000000000001724↗
  21. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectabl… Co-author DOI 10.1158/1078-0432.ccr-20-2974↗
  22. Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-19-3978↗
  23. A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-20-1025↗
  24. Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Patients with Metastatic Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-19-0650↗
  25. An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocar… Last author DOI 10.18632/oncotarget.27586↗
  26. The Significance of Ascites in Patients With Pancreatic Ductal Adenocarcinoma: A Case-Control Study. Co-author DOI 10.1097/mpa.0000000000001262↗
  27. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pa… Co-author DOI 10.1158/1078-0432.ccr-18-2992↗
  28. Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated Wit… Co-author DOI 10.1016/j.ijrobp.2017.10.001↗
  29. T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci.insight.122092↗
  30. Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Surgical Resection of Pancreatic Ductal Adenocarcinoma Appears to be Safe and Effective. Co-author DOI 10.1245/s10434-017-6134-6↗
  31. Stereotactic body radiation therapy for palliative management of pancreatic adenocarcinoma in elderly and medically inoperable patients. Co-author DOI 10.18632/oncotarget.24713↗
  32. Diagnostic intervals and pancreatic ductal adenocarcinoma (PDAC) resectability: a single-center retrospective analysis. Co-author DOI 10.21037/apc.2018.02.01↗
  33. Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. Co-author DOI 10.1002/cam4.1104↗
  34. Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. Co-author DOI 10.18632/oncotarget.17237↗
  35. A rare case of esophageal metastasis from pancreatic ductal adenocarcinoma: a case report and literature review. Co-author DOI 10.18632/oncotarget.18458↗
  36. Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000022↗
  37. Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-15-0200-t↗
  38. Long term survivors and immune biomarker analysis of Phase IIa, randomized study of GVAX pancreas and crs-207 immunotherapy in patients with metastatic pancrea… Co-author DOI 10.1186/2051-1426-3-s2-p102↗
  39. Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patient… Co-author DOI 10.1186/2051-1426-3-s2-p155↗
  40. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. Co-author DOI 10.1200/jco.2014.57.4244↗
  41. The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience. Co-author DOI 10.1245/s10434-014-4274-5↗
  42. A Phase IIb, randomized, multicenter study of the efficacy of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with pre… Last author DOI 10.1186/2051-1426-2-s3-p68↗
  43. Baseline hemoglobin-A1c impacts clinical outcomes in patients with pancreatic cancer. Co-author DOI 10.6004/jnccn.2014.0006↗
  44. Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor-vessel relat… Co-author DOI 10.1007/s13566-013-0115-6↗
  45. Current advances in immunotherapy for pancreatic cancer. First author DOI 10.1016/j.currproblcancer.2013.10.004↗
  46. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. Co-author DOI 10.1016/j.ijrobp.2013.03.032↗
  47. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. Co-author DOI 10.1097/cji.0b013e31829fb7a2↗
  48. Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality ther… Co-author DOI 10.3978/j.issn.2078-6891.2013.044↗
  49. A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Co-author DOI 10.1007/s00280-011-1704-y↗
  50. Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer. Co-author DOI 10.1007/s10637-012-9818-6↗

Trials 10

  1. Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. Principal investigator NCT04753879↗
  2. Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer Principal investigator NCT04177810↗
  3. A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer Principal investigator NCT03535727↗
  4. Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer Principal investigator NCT03190265↗
  5. GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab Principal investigator NCT02243371↗
  6. Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer Principal investigator NCT02324543↗
  7. A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer Study chair NCT02048384↗
  8. Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer Principal investigator NCT01417000↗
  9. Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer Principal investigator NCT01459614↗
  10. Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer Principal investigator NCT00836407↗

Grants 4

  1. Administrative Core P01CA247886↗
  2. Phase 2 Study of Folfirinox Followed by Ipilimumab/GVAX in Pancreatic Cancer R01FD004819↗
  3. Cyclophosphamide modified GM-CSF pancreatic tumor vaccine + listeria-mesothelin K23CA163672↗
  4. GVAX + CRS-207 Heterologous Prime Boost Vaccination with PD-1 Blockade AWARD pancan:2014-dung-le-md-gvax-crs-207-heterologous-prime-boost-va

Closest collaborators

The 25 strongest of 166 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniel A. Laheru · 41 shared papers, 2011–2026 · strength 3.81
  2. Elizabeth M. Jaffee · 29 shared papers, 1 shared grant, 2011–2026 · strength 3.71
  3. Lei Zheng · 26 shared papers, 1 shared grant, 2011–2026 · strength 2.96
  4. Ana De Jesus‐Acosta · 24 shared papers, 2012–2026 · strength 2.37
  5. Amol Kumar Narang · 16 shared papers, 2012–2026 · strength 1.74
  6. Joseph M. Herman · 21 shared papers, 2011–2026 · strength 1.65
  7. Katherine M. Bever · 10 shared papers, 2020–2026 · strength 1.61
  8. Nilofer Saba Azad · 7 shared papers, 1 shared grant, 2016–2025 · strength 1.31
  9. Robert A. Anders · 11 shared papers, 2011–2026 · strength 1.25
  10. Amy Hacker‐Prietz · 15 shared papers, 2013–2025 · strength 1.21
  11. Richard Andrew Burkhart · 8 shared papers, 2018–2026 · strength 1.19
  12. Hao Wang · 6 shared papers, 2022–2026 · strength 1.09
  13. Michael Jon Pishvaian · 5 shared papers, 2022–2026 · strength 0.99
  14. Jin Peng He · 10 shared papers, 2017–2023 · strength 0.95
  15. Won Jin Ho · 5 shared papers, 2020–2026 · strength 0.88
  16. Matthew John Weiss · 10 shared papers, 2015–2022 · strength 0.83
  17. Lauren M. Rosati · 9 shared papers, 2015–2025 · strength 0.81
  18. Christopher Lee Wolfgang · 13 shared papers, 2012–2022 · strength 0.80
  19. Elana Judith Fertig · 5 shared papers, 2020–2026 · strength 0.78
  20. Valerie Lee · 6 shared papers, 2017–2026 · strength 0.74
  21. Christopher L. Wolfgang · 7 shared papers, 2018–2025 · strength 0.74
  22. Lei Zheng · 6 shared papers, 2013–2025 · strength 0.72
  23. Timothy Michael Pawlik · 10 shared papers, 2012–2025 · strength 0.64
  24. Eric Scott Christenson · 3 shared papers, 2022–2026 · strength 0.60
  25. Colin Hill · 4 shared papers, 2022–2025 · strength 0.58

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.